Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
New pathogenic germline variants identified in mesothelioma.
Belcaid L, Bertelsen B, Wadt K, Tuxen I, Spanggaard I, Højgaard M, Benn Sørensen J, Ravn J, Lassen U, Cilius Nielsen F, Rohrberg K, Westmose Yde C. Belcaid L, et al. Among authors: spanggaard i. Lung Cancer. 2023 May;179:107172. doi: 10.1016/j.lungcan.2023.03.008. Epub 2023 Mar 15. Lung Cancer. 2023. PMID: 36944283 Free article. Review.
Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial.
Rodón J, Damian S, Furqan M, García-Donas J, Imai H, Italiano A, Spanggaard I, Ueno M, Yokota T, Veronese ML, Oliveira N, Li X, Gilmartin A, Schaffer M, Goyal L. Rodón J, et al. Among authors: spanggaard i. Nat Med. 2024 Jun;30(6):1645-1654. doi: 10.1038/s41591-024-02934-7. Epub 2024 May 6. Nat Med. 2024. PMID: 38710951 Free PMC article. Clinical Trial.
Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study.
Li BT, Meric-Bernstam F, Bardia A, Naito Y, Siena S, Aftimos P, Anderson I, Curigliano G, de Miguel M, Kalra M, Oh DY, Park JO, Postel-Vinay S, Rha SY, Satoh T, Spanggaard I, Michelini F, Smith A, Machado KK, Saura C; DESTINY-PanTumor01 study group. Li BT, et al. Among authors: spanggaard i. Lancet Oncol. 2024 Jun;25(6):707-719. doi: 10.1016/S1470-2045(24)00140-2. Epub 2024 May 3. Lancet Oncol. 2024. PMID: 38710187 Clinical Trial.
Copenhagen Prospective Personalized Oncology (CoPPO)-Clinical Utility of Using Molecular Profiling to Select Patients to Phase I Trials.
Tuxen IV, Rohrberg KS, Oestrup O, Ahlborn LB, Schmidt AY, Spanggaard I, Hasselby JP, Santoni-Rugiu E, Yde CW, Mau-Sørensen M, Nielsen FC, Lassen U. Tuxen IV, et al. Among authors: spanggaard i. Clin Cancer Res. 2019 Feb 15;25(4):1239-1247. doi: 10.1158/1078-0432.CCR-18-1780. Epub 2018 Oct 1. Clin Cancer Res. 2019. PMID: 30274980 Clinical Trial.
Application of cell-free DNA for genomic tumor profiling: a feasibility study.
Ahlborn LB, Rohrberg KS, Gabrielaite M, Tuxen IV, Yde CW, Spanggaard I, Santoni-Rugiu E, Nielsen FC, Lassen U, Mau-Sorensen M, Østrup O. Ahlborn LB, et al. Among authors: spanggaard i. Oncotarget. 2019 Feb 15;10(14):1388-1398. doi: 10.18632/oncotarget.26642. eCollection 2019 Feb 15. Oncotarget. 2019. PMID: 30858924 Free PMC article.
[Trends in oncological phase I trials].
Rohrberg KS, Qvortrup C, Højgaard M, Spanggaard I. Rohrberg KS, et al. Among authors: spanggaard i. Ugeskr Laeger. 2019 Oct 14;181(20A):V05190301. Ugeskr Laeger. 2019. PMID: 31610836 Free article. Review. Danish.
Modeling Metastatic Colonization in a Decellularized Organ Scaffold-Based Perfusion Bioreactor.
Rafaeva M, Horton ER, Jensen ARD, Madsen CD, Reuten R, Willacy O, Brøchner CB, Jensen TH, Zornhagen KW, Crespo M, Grønseth DS, Nielsen SR, Idorn M, Straten PT, Rohrberg K, Spanggaard I, Højgaard M, Lassen U, Erler JT, Mayorca-Guiliani AE. Rafaeva M, et al. Among authors: spanggaard i. Adv Healthc Mater. 2022 Jan;11(1):e2100684. doi: 10.1002/adhm.202100684. Epub 2021 Nov 17. Adv Healthc Mater. 2022. PMID: 34734500 Free PMC article.
29 results